©The Author(s) 2016.
World J Clin Oncol. Feb 10, 2016; 7(1): 87-97
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.87
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.87
Table 1 The different types of the above mentioned drugs according to their vesicant potential
| Neutrals | Inflammitants | Irritants | Exfoliants (may have low vesicant potential) | Vesicants |
| Asparaginase Bevacizumab bleomycin Bortezomib cetuximab, Cyclophosphamide | Bortezomib | Bendamustine | Aclacinomycin cisplatin Docetaxel liposomal Doxorubicin mitoxantrone Oxaliplatin paclitaxel | Actinomycin D |
| Cytarabine eribulin Fludarabine gemcitabine Ifosfamide | 5-Fluorouracil methotrexate raltitrexed | Bleomycin | Dactinomycin daunorubicin Doxorubicin epirubicin Idarubicin mitomycin C Vinblastine vindesine | |
| Melphalan rituximab | Carboplatin dexrasoxane | Vincristine vinorelbine | ||
| Trastuzumab | Etoposide | |||
| Teniposide | ||||
| Topotecan |
- Citation: Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016; 7(1): 87-97
- URL: https://www.wjgnet.com/2218-4333/full/v7/i1/87.htm
- DOI: https://dx.doi.org/10.5306/wjco.v7.i1.87